The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Trump Considering Dr. Scott Gottlieb to Head U.S. FDA

Trump Considering Dr. Scott Gottlieb to Head U.S. FDA

December 12, 2016 • By Toni Clarke

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Dr. Scott Gottlieb, a partner at one of the world’s largest venture capital funds and a former deputy commissioner at the U.S. Food and Drug Administration, is being considered by President-Elect Donald Trump to run the agency, according to sources close to the transition team.

You Might Also Like
  • Trump Chooses Gottlieb to Run FDA; Pharma Breathes Sigh of Relief
  • U.S. FDA Chief Gottlieb Resigns
  • Trump Nominee to Lead FDA Probed on Ties to Pharmacy Industry

Gottlieb, 44, a venture partner at New Enterprise Associates and resident fellow at the American Enterprise Institute, a conservative think tank based in Washington, D.C., is well known in health policy circles and is a frequent commentator on television and in print.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Gottlieb is being considered alongside Jim O’Neill, a self-declared libertarian and colleague of Peter Thiel, the co-founder of Mithril Capital Management who was an early Trump supporter and is now advising his transition team. Bloomberg News first reported that Trump was looking at O’Neill.

Trump, a Republican, takes office on Jan. 20.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michael Gaba, federal policy leader of law firm Holland and Knight’s national Healthcare and Life Sciences Team, says Gottlieb would be more palatable to more people than O’Neill, who believes drugs should be allowed on the market before their efficacy has been established, as long as they are safe.

Even the drug industry would likely oppose that stance, Gaba says, because companies want to be able to make credible claims that their products are effective in treating the diseases they say do.

“They want the FDA’s Good Housekeeping seal of approval,” Gaba says, adding, however, that drug makers would like to provide less data to get it.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Gottlieb would be a more traditional choice than O’Neill and fits the profile of what Trump’s administration seems to be looking for, he says.

“He leans right, he’s got experience in the agency, he’s got the M.D. credential, and he’s outspoken,” Gaba says.

The FDA historically has named someone with medical credentials to head the agency. O’Neill has none, though he served as principal associate deputy secretary of health and human services under the George W. Bush administration.

Gottlieb’s ties to the pharmaceutical industry run deep. He sits on the boards of multiple companies and advises others, including the British pharmaceutical giant GlaxoSmithKline Plc.

He is also a managing director of investment banking at T.R. Winston and Co., a Los Angeles-based, privately held investment bank that focuses on healthcare, clean energy and consumer technology.

According to its website, the firm provides services to a range of healthcare clients, “including companies engaged in the clinical development of new therapeutic compounds, drug discovery techniques, medical technologies and devices.”

Pages: 1 2 | Single Page

Filed Under: Legislation & Advocacy, Professional Topics Tagged With: Donald Trump, Drugs, FDA, Food and Drug Administration, regulatory

You Might Also Like:
  • Trump Chooses Gottlieb to Run FDA; Pharma Breathes Sigh of Relief
  • U.S. FDA Chief Gottlieb Resigns
  • Trump Nominee to Lead FDA Probed on Ties to Pharmacy Industry
  • FDA’s Gottlieb Eyes PBM Consolidation Impact on Generic Entry: CNBC

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.